A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia

R. Zanardi, E. Smeraldi

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Aim Evaluation of the effect of acetyl-l-carnitine (ALCAR) vs. amisulpride measured by total Hamilton Depression Rating Scale score (HAM-D21) in patients with pure dysthymia (DSM IV). Two hundred and four patients were randomised and treated with ALCAR 500 mg b.i.d. or amisulpride 50 mg u.i.d. in a double-blind study, for 12 weeks. Results A solid improvement of HAM-D21 was observed in both treatment groups throughout the study. The results did not disclose statistically significant differences between treatments, although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points. According to a non-inferiority margin of 3 (considered acceptable by recent published data) the primary end-point could have been fully satisfied. CDRS, MADRS and CGI, employed to further measure the clinical outcome, reported similar results in both treatment groups. The greater tolerability of ALCAR is of clinical relevance considering the chronicity of dysthymia, which often requires prolonged treatment.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalEuropean Neuropsychopharmacology
Volume16
Issue number4
DOIs
Publication statusPublished - May 2006

Fingerprint

Acetylcarnitine
Randomized Controlled Trials
Therapeutics
Double-Blind Method
Diagnostic and Statistical Manual of Mental Disorders
Outcome Assessment (Health Care)
Confidence Intervals
sultopride

Keywords

  • Acetyl-l-carnitine-ALCAR
  • Amisulpride
  • Dysthymia

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia. / Zanardi, R.; Smeraldi, E.

In: European Neuropsychopharmacology, Vol. 16, No. 4, 05.2006, p. 281-287.

Research output: Contribution to journalArticle

@article{580d4ebec00745d6b9c4f9891a0646e4,
title = "A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia",
abstract = "Aim Evaluation of the effect of acetyl-l-carnitine (ALCAR) vs. amisulpride measured by total Hamilton Depression Rating Scale score (HAM-D21) in patients with pure dysthymia (DSM IV). Two hundred and four patients were randomised and treated with ALCAR 500 mg b.i.d. or amisulpride 50 mg u.i.d. in a double-blind study, for 12 weeks. Results A solid improvement of HAM-D21 was observed in both treatment groups throughout the study. The results did not disclose statistically significant differences between treatments, although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points. According to a non-inferiority margin of 3 (considered acceptable by recent published data) the primary end-point could have been fully satisfied. CDRS, MADRS and CGI, employed to further measure the clinical outcome, reported similar results in both treatment groups. The greater tolerability of ALCAR is of clinical relevance considering the chronicity of dysthymia, which often requires prolonged treatment.",
keywords = "Acetyl-l-carnitine-ALCAR, Amisulpride, Dysthymia",
author = "R. Zanardi and E. Smeraldi",
year = "2006",
month = "5",
doi = "10.1016/j.euroneuro.2005.10.005",
language = "English",
volume = "16",
pages = "281--287",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "4",

}

TY - JOUR

T1 - A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia

AU - Zanardi, R.

AU - Smeraldi, E.

PY - 2006/5

Y1 - 2006/5

N2 - Aim Evaluation of the effect of acetyl-l-carnitine (ALCAR) vs. amisulpride measured by total Hamilton Depression Rating Scale score (HAM-D21) in patients with pure dysthymia (DSM IV). Two hundred and four patients were randomised and treated with ALCAR 500 mg b.i.d. or amisulpride 50 mg u.i.d. in a double-blind study, for 12 weeks. Results A solid improvement of HAM-D21 was observed in both treatment groups throughout the study. The results did not disclose statistically significant differences between treatments, although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points. According to a non-inferiority margin of 3 (considered acceptable by recent published data) the primary end-point could have been fully satisfied. CDRS, MADRS and CGI, employed to further measure the clinical outcome, reported similar results in both treatment groups. The greater tolerability of ALCAR is of clinical relevance considering the chronicity of dysthymia, which often requires prolonged treatment.

AB - Aim Evaluation of the effect of acetyl-l-carnitine (ALCAR) vs. amisulpride measured by total Hamilton Depression Rating Scale score (HAM-D21) in patients with pure dysthymia (DSM IV). Two hundred and four patients were randomised and treated with ALCAR 500 mg b.i.d. or amisulpride 50 mg u.i.d. in a double-blind study, for 12 weeks. Results A solid improvement of HAM-D21 was observed in both treatment groups throughout the study. The results did not disclose statistically significant differences between treatments, although the confidence interval for the non-inferiority of the primary end-point exceeded the pre-established limit of 2 by 0.46 points. According to a non-inferiority margin of 3 (considered acceptable by recent published data) the primary end-point could have been fully satisfied. CDRS, MADRS and CGI, employed to further measure the clinical outcome, reported similar results in both treatment groups. The greater tolerability of ALCAR is of clinical relevance considering the chronicity of dysthymia, which often requires prolonged treatment.

KW - Acetyl-l-carnitine-ALCAR

KW - Amisulpride

KW - Dysthymia

UR - http://www.scopus.com/inward/record.url?scp=33645981224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645981224&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2005.10.005

DO - 10.1016/j.euroneuro.2005.10.005

M3 - Article

VL - 16

SP - 281

EP - 287

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 4

ER -